Cargando…

Structural characterization of a human Fc fragment engineered for lack of effector functions

The first three-dimensional structure of a human Fc fragment genetically engineered for the elimination of its ability to mediate antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity is reported. When introduced into the lower hinge and C(H)2 domain of human IgG1 molec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oganesyan, Vaheh, Gao, Changshou, Shirinian, Lena, Wu, Herren, Dall’Acqua, William F.
Formato:	Texto
Lenguaje:	English
Publicado:	International Union of Crystallography 2008
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2467532/ https://www.ncbi.nlm.nih.gov/pubmed/18560159 http://dx.doi.org/10.1107/S0907444908007877

Ejemplares similares

Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-interferon antibody fragment and human interferon α-2A
por: Oganesyan, Vaheh, et al.
Publicado: (2008)

Generation and Characterization of an IgG4 Monomeric Fc Platform
por: Shan, Lu, et al.
Publicado: (2016)

Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab
por: Oganesyan, Vaheh, et al.
Publicado: (2015)

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody
por: Peng, Li, et al.
Publicado: (2015)

Structural insights into the interaction of human IgG1 with FcγRI: no direct role of glycans in binding
por: Oganesyan, Vaheh, et al.
Publicado: (2015)

In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance
por: Shan, Lu, et al.
Publicado: (2021)

Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody
por: Oganesyan, Vaheh, et al.
Publicado: (2018)

Mechanisms of Neutralization of a Human Anti-α-toxin Antibody
por: Oganesyan, Vaheh, et al.
Publicado: (2014)

Molecular basis for the mechanism of action of an anti-TACE antibody
por: Peng, Li, et al.
Publicado: (2016)

Long-acting antibody ligand mimetics for HER4-selective agonism
por: Shan, Lu, et al.
Publicado: (2020)

Enhancement of Immune Effector Functions by Modulating IgG’s Intrinsic Affinity for Target Antigen
por: Mazor, Yariv, et al.
Publicado: (2016)

A Novel Dual Expression Platform for High Throughput Functional Screening of Phage Libraries in Product like Format
por: Xiao, Xiaodong, et al.
Publicado: (2015)

Improving target cell specificity using a novel monovalent bispecific IgG design
por: Mazor, Yariv, et al.
Publicado: (2015)

Bi-Epitope SPR Surfaces: A Solution to Develop Robust Immunoassays
por: Peng, Li, et al.
Publicado: (2014)

Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody
por: Kasturirangan, Srinath, et al.
Publicado: (2017)

Mutations in an avian IgY-Fc fragment reveal the locations of monocyte Fc receptor binding sites
por: Taylor, Alexander I., et al.
Publicado: (2010)

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
por: van der Horst, Hilma J., et al.
Publicado: (2020)

Molecular basis for the antagonistic activity of an anti-CXCR4 antibody
por: Peng, Li, et al.
Publicado: (2015)

Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics
por: Yang, Chunpeng, et al.
Publicado: (2018)

IgG Fc engineering to modulate antibody effector functions
por: Wang, Xinhua, et al.
Publicado: (2017)

Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
por: Escobar-Cabrera, Eric, et al.
Publicado: (2017)

Engineered Fc-glycosylation switch to eliminate antibody effector function
por: Zhou, Qun, et al.
Publicado: (2020)

Fc-engineered antibodies with immune effector functions completely abolished
por: Wilkinson, Ian, et al.
Publicado: (2021)

Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen
por: Wang, Bo, et al.
Publicado: (2019)

Structure and Dynamics of a Site-Specific Labeled Fc Fragment with Altered Effector Functions
por: Gallagher, D. Travis, et al.
Publicado: (2019)

Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
por: Liu, Rena, et al.
Publicado: (2020)

Insights into the molecular basis of a bispecific antibody's target selectivity
por: Mazor, Yariv, et al.
Publicado: (2015)

Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
por: Mazor, Yariv, et al.
Publicado: (2017)

Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation
por: Rashid, Md Harunur
Publicado: (2022)

Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody
por: Zhang, Di, et al.
Publicado: (2016)

Engineered IgG1‐Fc – one fragment to bind them all
por: Lobner, Elisabeth, et al.
Publicado: (2016)

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities
por: Chen, Yaozong, et al.
Publicado: (2021)

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities
por: Chen, Yaozong, et al.
Publicado: (2022)

Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action
por: Geoghegan, James C., et al.
Publicado: (2016)

Stabilisation of the Fc Fragment of Human IgG1 by Engineered Intradomain Disulfide Bonds
por: Wozniak-Knopp, Gordana, et al.
Publicado: (2012)

Characterization and in vitro data of antibody drug conjugates (ADCs) derived from heterotrifunctional linker designed for the site-specific preparation of dual ADCs
por: Kumar, Amit, et al.
Publicado: (2018)

Discovery and characterization of potent IL-21 neutralizing antibodies via a novel alternating antigen immunization and humanization strategy
por: Varkey, Reena, et al.
Publicado: (2019)

Advances in Therapeutic Fc Engineering – Modulation of IgG-Associated Effector Functions and Serum Half-life
por: Saxena, Abhishek, et al.
Publicado: (2016)

Susceptibility variation of Malassezia pachydermatis to antifungal agents according to isolate source
por: Weiler, Caroline Borges, et al.
Publicado: (2013)

Vector induced skewing of antibody Fc-effector functions
por: Chung, A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rji33kq521l79cime4hilif6kg